Chase, Dana M <br/><br/>
Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II study.  [electronic resource] 

 -  Gynecologic oncology  Sep 2012 
 - 375-80 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1095-6859 
<br/><br/><label>Standard No.: </label>10.1016/j.ygyno.2012.06.002  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Angiogenesis Inhibitors--pharmacology<br/>Antibodies, Monoclonal, Humanized--pharmacology<br/>Bevacizumab<br/>Blood Vessels--pathology<br/>Carcinoma, Ovarian Epithelial<br/>Contrast Media<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Magnetic Resonance Imaging<br/>Middle Aged<br/>Neoplasms, Glandular and Epithelial--blood supply<br/>Neovascularization, Pathologic--pathology<br/>Ovarian Neoplasms--blood supply<br/>Peritoneal Neoplasms--blood supply<br/>Predictive Value of Tests<br/>Regional Blood Flow--drug effects<br/>Single-Blind Method